EpiEndo commences Phase 2a Trial for EP395 in COPD patients
EpiEndo Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapeutics for chronic inflammatory diseases, has received regulatory approval to commence a Phase 2a clinical trial with lead molecule EP395 in COPD (Chronic Obstructive Pulmonary Disease) patients. EP395 is an orally available macrolide or ‘Barriolide’, with reduced antimicrobial resistance potential, which aims to address the unmet medical need […]
